CD97 is a critical regulator of acute myeloid leukemia stem cell function

Gaëlle H. Martin, Nainita Roy, Sohini Chakraborty, Alexis Desrichard, Stephen S. Chung, Carolien M. Woolthuis, Wenhuo Hu, Iryna Berezniuk, Francine E. Garrett-Bakelman, Jörg Hamann, Sean M. Devlin, Timothy A. Chan, Christopher Y. Park

Research output: Contribution to journalArticle

Abstract

Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.

Original languageEnglish (US)
Pages (from-to)2362-2377
Number of pages16
JournalThe Journal of experimental medicine
Volume216
Issue number10
DOIs
StatePublished - Oct 7 2019
Externally publishedYes

Fingerprint

Myeloid Progenitor Cells
Acute Myeloid Leukemia
Stem Cells
Maintenance
G-Protein-Coupled Receptors
Therapeutics
Phenotype
Antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Martin, G. H., Roy, N., Chakraborty, S., Desrichard, A., Chung, S. S., Woolthuis, C. M., ... Park, C. Y. (2019). CD97 is a critical regulator of acute myeloid leukemia stem cell function. The Journal of experimental medicine, 216(10), 2362-2377. https://doi.org/10.1084/jem.20190598

CD97 is a critical regulator of acute myeloid leukemia stem cell function. / Martin, Gaëlle H.; Roy, Nainita; Chakraborty, Sohini; Desrichard, Alexis; Chung, Stephen S.; Woolthuis, Carolien M.; Hu, Wenhuo; Berezniuk, Iryna; Garrett-Bakelman, Francine E.; Hamann, Jörg; Devlin, Sean M.; Chan, Timothy A.; Park, Christopher Y.

In: The Journal of experimental medicine, Vol. 216, No. 10, 07.10.2019, p. 2362-2377.

Research output: Contribution to journalArticle

Martin, GH, Roy, N, Chakraborty, S, Desrichard, A, Chung, SS, Woolthuis, CM, Hu, W, Berezniuk, I, Garrett-Bakelman, FE, Hamann, J, Devlin, SM, Chan, TA & Park, CY 2019, 'CD97 is a critical regulator of acute myeloid leukemia stem cell function', The Journal of experimental medicine, vol. 216, no. 10, pp. 2362-2377. https://doi.org/10.1084/jem.20190598
Martin, Gaëlle H. ; Roy, Nainita ; Chakraborty, Sohini ; Desrichard, Alexis ; Chung, Stephen S. ; Woolthuis, Carolien M. ; Hu, Wenhuo ; Berezniuk, Iryna ; Garrett-Bakelman, Francine E. ; Hamann, Jörg ; Devlin, Sean M. ; Chan, Timothy A. ; Park, Christopher Y. / CD97 is a critical regulator of acute myeloid leukemia stem cell function. In: The Journal of experimental medicine. 2019 ; Vol. 216, No. 10. pp. 2362-2377.
@article{c3e90afeff7c4df49cd709e7b3e4c48a,
title = "CD97 is a critical regulator of acute myeloid leukemia stem cell function",
abstract = "Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.",
author = "Martin, {Ga{\"e}lle H.} and Nainita Roy and Sohini Chakraborty and Alexis Desrichard and Chung, {Stephen S.} and Woolthuis, {Carolien M.} and Wenhuo Hu and Iryna Berezniuk and Garrett-Bakelman, {Francine E.} and J{\"o}rg Hamann and Devlin, {Sean M.} and Chan, {Timothy A.} and Park, {Christopher Y.}",
year = "2019",
month = "10",
day = "7",
doi = "10.1084/jem.20190598",
language = "English (US)",
volume = "216",
pages = "2362--2377",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "10",

}

TY - JOUR

T1 - CD97 is a critical regulator of acute myeloid leukemia stem cell function

AU - Martin, Gaëlle H.

AU - Roy, Nainita

AU - Chakraborty, Sohini

AU - Desrichard, Alexis

AU - Chung, Stephen S.

AU - Woolthuis, Carolien M.

AU - Hu, Wenhuo

AU - Berezniuk, Iryna

AU - Garrett-Bakelman, Francine E.

AU - Hamann, Jörg

AU - Devlin, Sean M.

AU - Chan, Timothy A.

AU - Park, Christopher Y.

PY - 2019/10/7

Y1 - 2019/10/7

N2 - Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.

AB - Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.

UR - http://www.scopus.com/inward/record.url?scp=85072994376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072994376&partnerID=8YFLogxK

U2 - 10.1084/jem.20190598

DO - 10.1084/jem.20190598

M3 - Article

C2 - 31371381

AN - SCOPUS:85072994376

VL - 216

SP - 2362

EP - 2377

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 10

ER -